Meag Munich Ergo’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $52.1M | Sell |
66,841
-10,723
| -14% | -$8.33M | 1.47% | 27 |
|
|
2025
Q1 | $64.1M | Buy |
77,564
+7,403
| +11% | +$6.16M | 1.88% | 15 |
|
|
2024
Q4 | $54.3M | Buy |
70,161
+5,386
| +8% | +$4.46M | 1.72% | 20 |
|
|
2024
Q3 | $57.4M | Buy |
64,775
+1,614
| +3% | +$1.45M | 1.8% | 18 |
|
|
2024
Q2 | $57.2M | Buy |
63,161
+4,819
| +8% | +$3.85M | 1.9% | 14 |
|
|
2024
Q1 | $45.4M | Sell |
58,342
-12,316
| -17% | -$8.76M | 1.64% | 27 |
|
|
2023
Q4 | $41.2M | Buy |
70,658
+2,368
| +3% | +$1.38M | 1.56% | 27 |
|
|
2023
Q3 | $36.7M | Buy |
68,290
+7,894
| +13% | +$4.07M | 1.6% | 26 |
|
|
2023
Q2 | $28.3M | Sell |
60,396
-132,982
| -69% | -$55.8M | 1.23% | 35 |
|
|
2023
Q1 | $66.4M | Buy |
193,378
+23,729
| +14% | +$8M | 3.14% | 3 |
|
|
2022
Q4 | $62.1M | Sell |
169,649
-24,654
| -13% | -$8.74M | 3.34% | 3 |
|
|
2022
Q3 | $62.8M | Buy |
194,303
+14,833
| +8% | +$4.7M | 3.82% | 1 |
|
|
2022
Q2 | $58.2M | Buy |
179,470
+45,229
| +34% | +$13.6M | 3.47% | 2 |
|
|
2022
Q1 | $38.9M | Buy |
134,241
+20,806
| +18% | +$5.35M | 2.81% | 5 |
|
|
2021
Q4 | $31.6M | Buy |
113,435
+79,618
| +235% | +$20.2M | 2.24% | 16 |
|
|
2021
Q3 | $7.81M | Buy |
33,817
+1,906
| +6% | +$470K | 1.36% | 17 |
|
|
2021
Q2 | $7.32M | Buy |
+31,911
| New | +$6.41M | 0.7% | 29 |
|
|
2020
Q1 | – | Sell |
-13,114
| Closed | -$1.72M | – | 380 |
|
|
2019
Q4 | $1.72M | Sell |
13,114
-44,294
| -77% | -$5.13M | 0.18% | 132 |
|
|
2019
Q3 | $6.42M | Buy |
57,408
+21,580
| +60% | +$2.4M | 0.33% | 75 |
|
|
2019
Q2 | $4M | Hold |
35,828
| – | – | 0.31% | 75 |
|
|
2019
Q1 | $4.62M | Buy |
+35,828
| New | +$4.36M | 0.38% | 65 |
|
|
2018
Q4 | – | Sell |
-43,135
| Closed | -$4.58M | – | 376 |
|
|
2018
Q3 | $4.58M | Sell |
43,135
-57,988
| -57% | -$5.8M | 0.27% | 109 |
|
|
2018
Q2 | $8.72M | Sell |
101,123
-48,712
| -33% | -$4M | 0.54% | 46 |
|
|
2018
Q1 | $11.5M | Buy |
149,835
+27,533
| +23% | +$2.22M | 0.47% | 55 |
|
|
2017
Q4 | $10.5M | Sell |
122,302
-15,281
| -11% | -$1.3M | 0.4% | 69 |
|
|
2017
Q3 | $11.7M | Buy |
+137,583
| New | +$11.3M | 0.48% | 68 |
|
|
2016
Q4 | – | Sell |
-131,767
| Closed | -$10.5M | – | 307 |
|
|
2016
Q3 | $10.5M | Buy |
131,767
+35,165
| +36% | +$2.81M | 0.52% | 64 |
|
|
2016
Q2 | $7.58M | Buy |
+96,602
| New | +$7.27M | 0.69% | 53 |
|
|
2016
Q1 | – | Sell |
-118,166
| Closed | -$10.3M | – | 261 |
|
|
2015
Q4 | $10.3M | Sell |
118,166
-165,401
| -58% | -$13.7M | 0.51% | 71 |
|
|
2015
Q3 | $23.5M | Buy |
283,567
+89,845
| +46% | +$7.59M | 1.26% | 12 |
|
|
2015
Q2 | $16.2M | Sell |
193,722
-200,934
| -51% | -$15.3M | 0.83% | 32 |
|
|
2015
Q1 | $29M | Hold |
394,656
| – | – | 1.39% | 9 |
|
|
2014
Q4 | $27.4M | Sell |
394,656
-36,662
| -8% | -$2.47M | 1.24% | 17 |
|
|
2014
Q3 | $28M | Buy |
431,318
+117,966
| +38% | +$7.47M | 1.29% | 17 |
|
|
2014
Q2 | $19.5M | Buy |
313,352
+183,658
| +142% | +$11M | 0.85% | 39 |
|
|
2014
Q1 | $7.63M | Sell |
129,694
-8,703
| -6% | -$486K | 0.56% | 63 |
|
|
2013
Q4 | $7.07M | Buy |
138,397
+135,817
| +5,264% | +$6.8M | 0.42% | 84 |
|
|
2013
Q3 | $130K | Sell |
2,580
-133,080
| -98% | -$6.97M | 0.01% | 224 |
|
|
2013
Q2 | $6.71M | Buy |
+135,660
| New | +$7.38M | 0.51% | 74 |
|
Other funds holding LLY
Meag Munich Ergo's LLY Position: Q2 2025 in Review
Meag Munich Ergo reduced its Eli Lilly (LLY) stake by 14% in Q2 2025, selling an estimated $8.33M and leaving 66,841 shares worth $52.1M. The position accounts for 1.47% of the portfolio, ranked #27.
Meag Munich Ergo first reported a position in LLY in Q2 2013 and has held it in 39 quarters since. The position peaked at $66.4M in Q1 2023. 3,907 funds tracked by Wall St. Rank hold LLY as of Q2 2025.
- Meag Munich Ergo held 66,841 shares of Eli Lilly worth $52.1M as of Q2 2025.
- Meag Munich Ergo sold 10,723 Eli Lilly shares in Q2 2025, an estimated $8.33M.
- Eli Lilly made up 1.47% of Meag Munich Ergo's portfolio in Q2 2025, its #27 holding.
- Meag Munich Ergo first reported a position in Eli Lilly in Q2 2013 and has held it in 39 quarters since.
- Meag Munich Ergo's Eli Lilly position peaked at $66.4M in Q1 2023.
- 3,907 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2025.
Based on Meag Munich Ergo's 13F filing for Q2 2025, filed 16 Jul 2025.